Abeokuta

Researchers are evaluating the implementation and scale-up of Nigerias national sodium reduction program led by the Nigerian Agency for Food and Drug Administration and Control NAFDAC. This program uses the WHOs SHAKE package, which includes strategies like surveillance of salt intake, industry engagement, labeling standards, consumer education, and promoting healthy eating environments to reduce sodium intake and prevent hypertension. The study uses a type III hybrid, mixed methods design to assess the programs progress and effectiveness in real-world settings. The study involves enrolling adult household representatives from three Nigerian states to participate in repeated waves of data collection. Participants take part in surveys such as the STEPs survey, provide 24-hour and spot urine samples, blood samples for fatty acid estimation, and complete multiple 24-hour dietary recalls. These assessments occur at baseline Wave 1, and follow-ups at around 18 months Wave 2 and 36 months Wave 3 to monitor dietary sodium sources, population sodium intake, and program implementation outcomes. Participants will be involved in interviews, surveys, and biological sample collections over the study period. Researchers will use various frameworks and methods to evaluate program reach, adoption, feasibility, fidelity, acceptability, and cost. Key outcomes include changes in mean population sodium intake and 24-hour urinary sodium from baseline through follow-up waves, along with shifts in dietary sources of sodium and knowledge, attitudes, and behaviors about sodium intake. The total participation period spans approximately three years, with repeated assessments to track progress and impact.

Researchers are establishing the International Registry to Improve Outcomes in Men with Advanced Prostate Cancer IRONMAN as a prospective, global group of at least 5,000 men with advanced prostate cancer, including those with metastatic hormone-sensitive prostate cancer mHSPC and metastatic castration-resistant prostate cancer M0M1 CRPC. This study aims to better understand variations in care and treatment across different countries and medical settings by collecting detailed patient data over time. Participants will receive standard care drugs routinely used for metastatic prostate cancer based on local practices. Data collection begins at enrollment and continues for at least five years. Blood samples and tumor tissue, when possible, will be collected at enrollment, treatment changes, and follow-ups to study molecular markers linked to treatment response and resistance. Patient-reported outcome measures PROMs will be gathered every three months, and physicians will provide treatment and follow-up information regularly. During the study, participants will provide health and treatment information through questionnaires, with regular monitoring of survival, adverse events, and comorbidities. Blood samples will support future research to identify biomarkers. The main outcome is observing practice patterns over five years to help improve understanding of treatment sequences that optimize survival and quality of life for men with advanced prostate cancer.